GlassScriptPhysician profile
Adrianna Williamson
NPI 1285172619
$3,732.82
in general payments reported to CMS, 2019-2025
27 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.51 · 2022: $316 · 2023: $1,158 · 2024: $1,069 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.40 | 2021-2025 | |
| Lilly USA, LLC | $450.64 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $381.56 | 2021-2025 | |
| Novo Nordisk INC | $283.16 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.08 | 2022-2025 | Jardiance |
| Tris Pharma INC | $207.45 | 2023-2025 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.47 | 2022-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $129.07 | 2022-2025 | Xarelto, Spravato |
| Amgen INC. | $119.52 | 2022-2025 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $89.62 | 2023-2024 | |
| Exact Sciences Corporation | $75.42 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $60.23 | 2022-2023 | Trintellix |
| Abbott Laboratories | $58.55 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $58.29 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $50.40 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.43 | 2023-2024 | Shingrix, Arexvy, Boostrix |
| Idorsia Pharmaceuticals US INC | $44.37 | 2022-2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $30.92 | 2024 | Voquezna |
| Amneal Pharmaceuticals LLC | $28.95 | 2023 | Unithroid |
| Scpharmaceuticals INC. | $20.21 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.02 | 2022 | |
| Medtronic, INC. | $18.51 | 2024 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2025 | Farxiga |
| Astellas Pharma US INC | $17.54 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $13.35 | 2024 | Inspire |
| Impel Pharmaceuticals INC. | $12.81 | 2022 | |
| Ibsa Pharma INC. | $12.70 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianna Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.